EUVIMEDEUVIMED entdecken
Crossref

Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma

Klaudia Borbényi-Galambos, Katalin Erdélyi, Tamás Ditrói, Eszter Petra Jurányi, Noémi Szántó, Réka Szatmári, Ágnes Czikora, Edward E Schmidt, Dorottya Garai, Mihály Cserepes, Gabriella Liszkay, Erika Tóth und 2 weitere

Cell Metabolism · 2025-05 · 37 (5) · 1171-1188.e9

DOI: 10.1016/j.cmet.2025.01.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2025-05. Verfasst von Klaudia Borbényi-Galambos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary;…. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Magyar Tudományos Akadémia, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Richter Gedeon Talentum Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF V600E-inhibition effectively treats melanoma, but acquired resistance rapidly develops. Protein expression profiles, mitochondrial energetics, metabolomics and fluxomics data in cell line, xenograft, and patient-derived xenograft systems revealed that concerted reprogramming of metabolic pathways (including glutaminolysis, glycolysis, TCA cycle, electron transport chain [ETC], and transsulfuration), along with an immediate cytoprotective response to drug-induced oxidative stress, underpins drug-tolerant persister cancer cell survival. Realignment of cysteine (Cys) metabolism, in particular an immediate upregulation of cystathionine-γ-lyase (CSE), was vital in persister cells. The oxidative cellular environment, drug-induced elevated cystine uptake and oxidative Cys catabolism, increased intracellular cystine/Cys ratios, thereby favoring cystine as a CSE substrate. This produces persulfides and hydrogen sulfide to protect protein thiols and support elevated energy demand in persister cells. Combining BRAF V600E inhibitors with CSE inhibitors effectively diminished proliferative relapse in culture models and increased progression-free survival of xenografted mice. This, together with induced CSE expression in patient samples under BRAF-V600E-inhibition, reveals an approach to increase BRAF-V600E-targeted therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafDrug Resistance, NeoplasmHumansAnimalsMiceCell Line, TumorCystathionine gamma-LyaseCysteineXenograft Model Antitumor Assays

Stichwörter der Autor:innen

BRAF V600E targeted therapy resistancecystathionine γ-lyasecysteine metabolismfluxomics of metabolic reprogramminghydrogen sulfidemelanomapersister cellspersulfideredox regulationtranssulfuration

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanCystathionine gamma-LyaseCysteine

Autor:innen und Institutionen

  • Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary; Kálmán Laki Doctoral School, University of Debrecen, Debrecen, Hajdú-…
  • Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary.
  • Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary; Semmelweis University Doctoral School, Semmelweis University, Budapes…
  • Department of Anatomy and Histology, HUN-REN-UVMB Laboratory of Redox Biology, University of Veterinary Medicine, Budapest, 1078, Hungary; Department of Microbiology and Cell Biology, Montana State University, Bozeman,…
  • Department of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary.
  • Department of Dermatology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, 1122, Hungary.

Förderung

  • Magyar Tudományos Akadémia
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • Richter Gedeon Talentum Foundation
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Borbényi-Galambos, K., Erdélyi, K., Ditrói, T., Jurányi, E. P., Szántó, N., Szatmári, R., Czikora, Á., Schmidt, E. E., Garai, D., Cserepes, M., Liszkay, G., Tóth, E., Tóvári, J., & Nagy, P. (2025). Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma. Cell Metabolism, 37(5), 1171-1188.e9. https://doi.org/10.1016/j.cmet.2025.01.021

Vancouver

Borbényi-Galambos K, Erdélyi K, Ditrói T, Jurányi EP, Szántó N, Szatmári R, et al. Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma. Cell Metabolism. 2025;37(5):1171-1188.e9. doi:10.1016/j.cmet.2025.01.021

BibTeX
@article{BorbnyiGalambos2025,
  author = {Borbényi-Galambos, Klaudia and Erdélyi, Katalin and Ditrói, Tamás and Jurányi, Eszter Petra and Szántó, Noémi and Szatmári, Réka and Czikora, Ágnes and Schmidt, Edward E and Garai, Dorottya and Cserepes, Mihály and Liszkay, Gabriella and Tóth, Erika and Tóvári, József and Nagy, Péter},
  title = {Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma},
  journal = {Cell Metabolism},
  year = {2025},
  volume = {37},
  number = {5},
  pages = {1171--1188.e9},
  doi = {10.1016/j.cmet.2025.01.021}
}
Kostenlos starten →